Oral H1N1 influenza vaccine: Phase I data

A double-blind, placebo-controlled, dose-escalation, U.S. Phase I trial in 36 healthy volunteers showed that Vaxart's oral H1N1 influenza vaccine led to no vaccine-related significant adverse events a...